
	Mr. R. Richard Wieland, II, also known as Rich, MBA, served as the Chief Financial Officer and an Executive Vice President of Unilife Corporation since June 8, 2010 until March 2014. Mr. Wieland served as the Principal Accounting Officer of Unilife Corporation until July 2010. He served as the Chief Financial Officer of Cytochroma Inc. since May 2008. He served as the President and Chief Operating Offer of Option Care Inc. He has 40 years of experience in finance and financial management, at both public and private companies, he also has strong leadership skills, extensive experience managing finance departments and significant expertise in the capital markets. Earlier in his career, Mr. Wieland held senior level financial and management positions at BioGenex Laboratories, Cancer Treatment Centers, Fujisawa USA, LyphoMed and Procter &amp; Gamble. He served as an Executive Vice President and Chief Financial Officer of Advanced Life Sciences Holdings Inc. from June 2004 to April 18, 2008 and also served as its Principal Accounting Officer. He served as Executive Vice President &amp; Chief Financial Officer of Advanced Life Sciences Inc., a subsidiary of Advanced Life Sciences Holdings Inc. since June 2004. From May 2000 to April 2002, Mr. Wieland served as Executive Vice President and Chief Financial Officer of MediChem Life Sciences Inc., where he was responsible for overseeing the financial aspects of acquiring ThermoGen and Emerald Biostructures as MediChem subsidiaries and assisting in the financial effort to complete MediChem&#39;s initial public offering. He served as a Director of Option Care, Inc. He served as a Member of the National Investor Relations Institute, Financial Executives International and the U.S. Army Signal Corps. Mr. Wieland holds a BA in Accounting and Economics from Monmouth College and an MBA from Washington University.
